Asian Penny Stock Highlights: Crypto Flow Technology And 2 More Promising Picks

As Asian markets continue to show resilience, particularly with Chinese equities gaining momentum and Japan's indices reaching new highs, investors are increasingly looking toward emerging opportunities in the region. Penny stocks, often associated with smaller or newer companies, remain a relevant area for those seeking growth potential at lower price points. By focusing on strong balance sheets and solid fundamentals, these stocks can present attractive prospects without many of the typical risks associated with this sector.

Top 10 Penny Stocks In Asia

Name	Share Price	Market Cap	Rewards & Risks
Guoquan Food (Shanghai) (SEHK:2517)	HK$3.10	HK$8.13B	✅ 5 ⚠️ 1 View Analysis >
Yonghe Medical Group (SEHK:2279)	HK$2.32	HK$1.16B	✅ 4 ⚠️ 1 View Analysis >
Lever Style (SEHK:1346)	HK$1.36	HK$842.99M	✅ 3 ⚠️ 1 View Analysis >
Asia Medical and Agricultural Laboratory and Research Center (SET:AMARC)	THB3.84	THB1.59B	✅ 2 ⚠️ 3 View Analysis >
CNMC Goldmine Holdings (Catalist:5TP)	SGD1.42	SGD575.51M	✅ 4 ⚠️ 2 View Analysis >
Xtep International Holdings (SEHK:1368)	HK$4.18	HK$11.39B	✅ 5 ⚠️ 1 View Analysis >
Yangzijiang Shipbuilding (Holdings) (SGX:BS6)	SGD4.02	SGD15.82B	✅ 4 ⚠️ 2 View Analysis >
TeleChoice International (SGX:T41)	SGD0.24	SGD108.72M	✅ 4 ⚠️ 2 View Analysis >
Scott Technology (NZSE:SCT)	NZ$2.45	NZ$206.03M	✅ 4 ⚠️ 1 View Analysis >
Lee Feed Mill (SET:LEE)	THB2.44	THB2.17B	✅ 2 ⚠️ 2 View Analysis >

Click here to see the full list of 952 stocks from our Asian Penny Stocks screener.

Here we highlight a subset of our preferred stocks from the screener.

Crypto Flow Technology (SEHK:8198)

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Crypto Flow Technology Limited is an investment holding company offering storage, electricity, and related services in Hong Kong and the United States with a market cap of HK$1.33 billion.

Operations: The company's revenue is derived from several segments, including HK$0.09 million from its Analysis Platform, HK$1.68 million from its Money Lending Business, HK$0.29 million through Exchange and OTC Services, and HK$45.18 million from Big Data Centre services outside of the PRC.

Market Cap: HK$1.33B

Crypto Flow Technology Limited, with a market cap of HK$1.33 billion, is currently unprofitable and pre-revenue in some segments. Its revenue primarily stems from Big Data Centre services outside the PRC at HK$45.18 million, while other segments contribute minimally. The company reported a significant net loss increase to HK$89.23 million for 2025 due to reduced data centre operations and increased expenses in R&D and marketing. Despite having no debt and stable short-term asset coverage over liabilities, it faces challenges with high volatility, limited cash runway under a year, and an inexperienced management team averaging 1.1 years tenure.

• Take a closer look at Crypto Flow Technology's potential here in our financial health report.
• Learn about Crypto Flow Technology's historical performance here.

Majestic Dragon AeroTech Holdings (SEHK:918)

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Majestic Dragon AeroTech Holdings Limited is an investment holding company involved in the wholesale of timepieces, accessories, and garment and sportswear products across Africa, Hong Kong, Mainland China, and Taiwan with a market cap of HK$1.29 billion.

Operations: The company's revenue is primarily derived from its Wholesale Business, which generated HK$124.85 million, followed by the Unmanned Aerial Vehicles Business at HK$50.62 million and Property Investment at HK$0.95 million.

Market Cap: HK$1.29B

Majestic Dragon AeroTech Holdings, with a market cap of HK$1.29 billion, has shown financial improvement by becoming profitable over the past year. The company reduced its debt to equity ratio significantly from 559.2% to 2% over five years and maintains strong short-term asset coverage over liabilities. Despite stable weekly volatility at 12%, it remains higher than most Hong Kong stocks. The company's earnings are impacted by a large one-off loss of HK$8.2 million, and its return on equity is low at 0.6%. Additionally, the board lacks experience with an average tenure of 2.8 years.

• Click to explore a detailed breakdown of our findings in Majestic Dragon AeroTech Holdings' financial health report.
• Gain insights into Majestic Dragon AeroTech Holdings' historical outcomes by reviewing our past performance report.

Jiangsu Huifeng Bio Agriculture (SZSE:002496)

Simply Wall St Financial Health Rating: ★★★★★☆

Overview: Jiangsu Huifeng Bio Agriculture Co., Ltd. operates in the agricultural sector and has a market capitalization of CN¥3.69 billion.

Operations: Jiangsu Huifeng Bio Agriculture Co., Ltd. has not reported any specific revenue segments.

Market Cap: CN¥3.69B

Jiangsu Huifeng Bio Agriculture Co., Ltd., with a market cap of CN¥3.69 billion, faces challenges despite recent revenue growth, reporting CN¥107.56 million in Q1 2026 sales compared to CN¥74.02 million a year ago. However, net income dropped significantly to CN¥0.58 million from CN¥15.66 million the previous year, reflecting ongoing profitability issues and increasing losses over five years at 21.5% annually. The company's short-term assets of CN¥262.7M fall short against liabilities of CN¥787.7M, raising liquidity concerns further highlighted by auditor doubts about its going concern status despite recent capital raising efforts through private placements totaling CNY 300 million.

• Click here and access our complete financial health analysis report to understand the dynamics of Jiangsu Huifeng Bio Agriculture.
• Explore historical data to track Jiangsu Huifeng Bio Agriculture's performance over time in our past results report.

Turning Ideas Into Actions

• Unlock more gems! Our Asian Penny Stocks screener has unearthed 949 more companies for you to explore.Click here to unveil our expertly curated list of 952 Asian Penny Stocks.
• Ready For A Different Approach? AI is about to change healthcare. These 122 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com